Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Literature
1.
Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. 2007 ASCO Annual Meeting
2.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20PubMedCrossRef
3.
Sasako M, Yamaguchi T, Kinorshita T, et al. Randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study). (Abstract No. 8). 2007 ASCO Gastrointestinal Cancers Symposium Orlando, FL: American Society of Clinical Oncology; 2007
4.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2: 98–107PubMedCrossRef
5.
Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?. Ann Surg Oncol 2007;14:2691–5PubMedCrossRef
6.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMed
7.
Mansour JC, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007 Oct 2; [Epub ahead of print]
8.
Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol 2007 Oct 12; [Epub ahead of print]
9.
10.
Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRef
11.
12.
Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef
13.
Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States?. Ann Surg Oncol 2004; 11: 727–30. PubMedCrossRef
14.
Wu CW, Hsiung SA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol 2006;7:309–15PubMedCrossRef
15.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30PubMedCrossRef
16.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9: 220–1PubMedCrossRef
17.
Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 8: 59–62CrossRef
18.
Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449–61PubMedCrossRef
19.
Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80: 16–24PubMed
20.
Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit?. Ann Surg Oncol 2000; 7: 253–5PubMedCrossRef
21.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90PubMedCrossRef
22.
Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39PubMedCrossRef
23.
Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9PubMedCrossRef
24.
Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283–91PubMedCrossRef
25.
Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9: 607–9PubMed
26.
Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9: 941–3PubMed
27.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2007 Oct 17; [Epub ahead of print]; DOI: 10.​1245/​s10434-007-9612-4
28.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef
29.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10: 718–21PubMedCrossRef
30.
Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5: 737–45PubMedCrossRef
31.
Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 1555–6; author reply 1556
32.
Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006;6:931–9PubMedCrossRef
33.
Metadata
Title
Controversy in the Treatment of Gastric Cancer
Authors
Michael Fatouros, MD
Dimosthenis Ziogas, MD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9764-2

Other articles of this Issue 6/2008

Annals of Surgical Oncology 6/2008 Go to the issue

Hepatic and Pancreatic Tumors

Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis

Gastrointestinal Oncology

Significance of the Lymph Node Ratio in Stage III Colon Cancer

Breast Oncology

Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer

Breast Oncology

Staging of Invasive Breast Carcinoma Patients With T4anyNM0 and T1–3N3M0

Breast Oncology

Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial

Hepatic and Pancreatic Tumors

Results of Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases